Heat Shock Protein 90 (HSP90) and Immune Regulation

Bo-Kyung Kim; So-Youn Woo

doi:10.4167/jbv.2015.45.1.62

Journal List > J Bacteriol Virol > v.45(1) > 1034204

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Kim and Woo: Heat Shock Protein 90 (HSP90) and Immune Regulation

Research Update (Minireview)

J Bacteriol Virol 2015;45(1):62-66.

Published online: 9 February 2015

DOI: https://doi.org/10.4167/jbv.2015.45.1.62

Heat Shock Protein 90 (HSP90) and Immune Regulation

Bo-Kyung Kim, So-Youn Woo^*

Departments of Microbiology, School of Medicine, Ewha Womans University, Seoul, Korea

^*Corresponding author: So-Youn Woo. #207, Departments of Microbiology, School of Medicine, Ewha Womans University Seoul, 158-710, Korea. Phone: +82-2-2650-5737, Fax: +82-2-2653-8891, e-mail: soyounwoo@ewha.ac.kr

^** This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (2013R1A1A3A04006995).

Received 2 February 20156 February 2015 Accepted 17 February 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Heat shock protein 90 (HSP90) is involved in conformational and structural maturation of signalling molecules and transcription factors in immune reaction. HSP90 inhibitors induce immune modulation via anti-inflammatory effect, regulating humoral and cellular immune responses. Therefore, HSP90 inhibitors potentially useful target for the autoimmune disease and chronic inflammatory diseases.

Keywords: Heat shock protein 90 (HSP90), Anti-inflammatory, HSP90 inhibitor, IL-17, Act1

REFERENCES

1). Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol. 2010; 11:515–28.

2). Laederich MB, Degnin CR, Lunstrum GP, Holden P, Horton WA. Fibroblast growth factor receptor 3 (FGFR3) is a strong heat shock protein 90 (Hsp90) client: implications for therapeutic manipulation. J Biol Chem. 2011; 286:19597–604.

3). de Jong PR, Schadenberg AW, Jansen NJ, Prakken BJ. Hsp70 and cardiac surgery: molecular chaperone and inflammatory regulator with compartmentalized effects. Cell Stress Chaperones. 2009; 14:117–31.

4). Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013; 14:e358–69.

5). Shimp SK 3rd, Chafin CB, Regna NL, Hammond SE, Read MA, Caudell DL, et al. Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus. Cell Mol Immunol. 2012; 9:255–66.

6). Hacker S, Lambers C, Hoetzenecker K, Pollreisz A, Aigner C, Lichtenauer M, et al. Elevated HSP27, HSP70 and HSP90 alpha in chronic obstructive pulmonary disease: markers for immune activation and tissue destruction. Clin Lab. 2009; 55:31–40.

7). Hance MW, Dole K, Gopal U, Bohonowych JE, Jezierska-Drutel A, Neumann CA, et al. Secreted Hsp90 is a novel regulator of the epithelial to mesenchymal transition (EMT) in prostate cancer. J Biol Chem. 2012; 287:37732–44.

8). Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutic agents. Expert Opin Emerg Drugs. 2002; 7:277–88.

9). Poulaki V, Iliaki E, Mitsiades N, Mitsiades CS, Paulus YN, Bula DV, et al. Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis. FASEB J. 2007; 21:2113–23.

10). Ying W, Du Z, Sun L, Foley KP, Proia DA, Blackman RK, et al. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther. 2012; 11:475–84.

11). Lilja A, Weeden CE, McArthur K, Nguyen T, Donald A, Wong ZX, et al. HSP90 Inhibition Suppresses Lipopolysaccharide-Induced Lung Inflammation In Vivo. PLoS One. 2015; 10:e0114975.

12). Jin HS, Park JK, Jo EK. Toll-like Receptors and NOD-like Receptors in Innate Immune Defense during Pathogenic Infection. J Bacteriol Virol. 2014; 44:215–25.

13). Woodley DT, Burgeson RE, Lunstrum G, Bruckner-Tuderman L, Reese MJ, Briggaman RA. Epidermolysis bullosa acquisita antigen is the globular carboxyl terminus of type VII procollagen. J Clin Invest. 1988; 81:683–7.

14). Tukaj S, Kleszczyński K, Vafia K, Groth S, Meyersburg D, Trzonkowski P, et al. Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid. PLoS One. 2013; 8:e70496.

15). Tukaj S, Grüner D, Zillikens D, Kasperkiewicz M. Hsp90 blockade modulates bullous pemphigoid IgG-induced IL-8 production by keratinocytes. Cell Stress Chaperones. 2014; 19:887–94.

16). Tukaj S, Tiburzy B, Manz R, de Castro Marques A, Orosz A, Ludwig RJ, et al. Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses. Exp Dermatol. 2014; 23:585–90.

17). Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012; 30:221–41.

18). Kasperkiewicz M, Müller R, Manz R, Magens M, Hammers CM, Somlai C, et al. Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets. Blood. 2011; 117:6135–42.

19). Tukaj S, Zillikens D, Kasperkiewicz M. Inhibitory effects of heat shock protein 90 blockade on proinflammatory human Th1 and Th17 cell subpopulations. J Inflamm (Lond). 2014; 11:10.

20). Collins CB, Aherne CM, Yeckes A, Pound K, Eltzschig HK, Jedlicka P, et al. Inhibition of N-terminal ATPase on HSP90 attenuates colitis through enhanced Treg function. Mucosal Immunol. 2013; 6:960–71.

21). Gong J, Zhu B, Murshid A, Adachi H, Song B, Lee A, et al. T cell activation by heat shock protein 70 vaccine requires TLR signaling and scavenger receptor expressed by endothelial cells-1. J Immunol. 2009; 183:3092–8.

22). Murshid A, Gong J, Calderwood SK. Hsp90-peptide complexes stimulate antigen presentation through the class II pathway after binding scavenger receptor SREC-I. Immunobiology. 2014; 219:924–31.

23). Conti HR, Shen F, Nayyar N, Stocum E, Sun JN, Lindemann MJ, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009; 206:299–311.

24). Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006; 203:2577–87.

25). Qian Y, Liu C, Hartupee J, Altuntas CZ, Gulen MF, Jane-Wit D, et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol. 2007; 8:247–56.

26). Schwandner R, Yamaguchi K, Cao Z. Requirement of tumor necrosis factor receptor-associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med. 2000; 191:1233–40.

27). Wang C, Wu L, Bulek K, Martin BN, Zepp JA, Kang Z, et al. The psoriasis-associated D10N variant of the adaptor Act1 with impaired regulation by the molecular chaperone hsp90. Nat Immunol. 2013; 14:72–81.

28). Wu L, Wang C, Boisson B, Misra S, Rayman P, Finke JH, et al. The differential regulation of human ACT1 isoforms by Hsp90 in IL-17 signaling. J Immunol. 2014; 193:1590–9.

TOOLS

Similar articles